[
 {
  "title": "Immunotherapies for Cancer",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A pioneer in the field of immunotherapies for cancer has been studying how to harness the immune system to treat cancer. This includes the use of non-specific therapies such as interleukin-2, the discovery of tumor-infiltrating lymphocytes, checkpoint inhibitors, CAR T-cells, and adoptive cell therapy. Recent discoveries with respect to tumor antigenicity have also been made.",
  "content_length": 378,
  "content_tokens": 81,
  "embedding": []
 },
 {
  "title": "Cancer Treatment in the 1970s",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "In the early 1970s, the intuition to utilize lymphocytes for cancer treatment was developed. The problem with chemotherapy and the promise of immunotherapy were also discussed. The immune system's role in allowing cancer to proliferate was also explored.",
  "content_length": 254,
  "content_tokens": 47,
  "embedding": []
 },
 {
  "title": "Interleukin-2 and Cancer Regression",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The use of interleukin-2 to mediate cancer regression was discovered. The immunogenic nature of certain cancers and the role of mutations in cancer were also discussed.",
  "content_length": 168,
  "content_tokens": 35,
  "embedding": []
 },
 {
  "title": "CAR T Cell Therapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The improbable story of how CAR T cell therapy was developed was shared. This includes the discovery of tumor infiltrating lymphocytes (TIL) and the engineering of T cells to recognize specific antigens.",
  "content_length": 203,
  "content_tokens": 41,
  "embedding": []
 },
 {
  "title": "Checkpoint Inhibitors and Adoptive Cell Therapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The role of checkpoint inhibitors in cancer therapy and the promise of adoptive cell therapy were discussed. There is optimism for using immunotherapy to cure all cancers.",
  "content_length": 171,
  "content_tokens": 30,
  "embedding": []
 },
 {
  "title": "Human Side of Cancer",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The human side of cancer was discussed, emphasizing the importance of understanding the patient's perspective and experience.",
  "content_length": 125,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Alzheimer’s Disease, Cancer, Exercise, Nutrition, and Fasting",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting were provided. These insights translate complex scientific topics into actionable insights.",
  "content_length": 172,
  "content_tokens": 31,
  "embedding": []
 },
 {
  "title": "Impact of Stress on Health",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The impact of stress on our physical and emotional health",
  "content_length": 57,
  "content_tokens": 10,
  "embedding": []
 },
 {
  "title": "Optimizing Brain Health",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Optimizing brain health: Alzheimer's disease risk factors, APOE, prevention strategies, and more",
  "content_length": 96,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Training Principles for Longevity",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Training principles for longevity",
  "content_length": 33,
  "content_tokens": 4,
  "embedding": []
 },
 {
  "title": "Preventing Cardiovascular Disease",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more",
  "content_length": 111,
  "content_tokens": 20,
  "embedding": []
 },
 {
  "title": "Pros and Cons of GLP-1 Weight Loss Drugs and Metformin",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent",
  "content_length": 80,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Overcoming Trauma and Finding Inner Peace",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Overcoming trauma, finding inner peace, and living a meaningful and fulfilling life",
  "content_length": 83,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Cell and Gene Therapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The history of the cell, cell therapy, gene therapy, and more",
  "content_length": 61,
  "content_tokens": 14,
  "embedding": []
 },
 {
  "title": "Alzheimer's Disease and Lifestyle Factors",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Alzheimer’s disease: Rhonda’s evolved thinking on neurodegenerative diseases; The breakdown of the blood-brain barrier in neurodegenerative disease; An explanation for the observation that type 2 diabetes increases risk of Alzheimer’s disease; The role of omega-3 fatty acids (EPA and DHA) in brain health and prevention of neurodegeneration; Blood pressure: an important modifiable lifestyle factor that can affect Alzheimer's disease risk; Possible mechanisms by which exercise reduces the risk of Alzheimer’s disease; The relationship between cardiorespiratory fitness and dementia risk",
  "content_length": 589,
  "content_tokens": 124,
  "embedding": []
 },
 {
  "title": "Exercise and Cancer Risk",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "How exercise may reduce the risk of cancer; The overarching impact of exercise on health, and the importance of focusing the factors that matter most; Exercise as an intervention for poor sleep habits",
  "content_length": 200,
  "content_tokens": 36,
  "embedding": []
 },
 {
  "title": "Alcohol Consumption and Health",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Impact of alcohol consumption on breast cancer risk and overall health",
  "content_length": 70,
  "content_tokens": 12,
  "embedding": []
 },
 {
  "title": "Protein Consumption and Longevity",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The longevity benefits of consuming adequate protein and strength training to preserve muscle mass and strength; How to get enough of the right kind of protein in your diet",
  "content_length": 172,
  "content_tokens": 30,
  "embedding": []
 },
 {
  "title": "Fasting and Health",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Fasting: weighing the risk vs. reward",
  "content_length": 37,
  "content_tokens": 9,
  "embedding": []
 },
 {
  "title": "Spontaneous Regression of Cancer",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A 68-year-old patient came in complaining of right upper quadrant pain. 11 or 12 years earlier, that patient had been seen at the hospital. He had gastric cancer (a stomach cancer) and underwent a laparotomy. The surgeon at the time noted a tumor encompassing about three-quarters of the stomach; there were multiple liver metastasis deposits that were biopsied and shown to be the gastric cancer that had spread, multiple enlarged lymph nodes. Part of the stomach was removed and the rest of the disease was left in place. This was now 12 years later; the patient has lived 10-11 years normally after this. It was a cancer that had spontaneously disappeared over time in the absence of any therapy. One of the rarest events in medicine, and that is to have the spontaneous regression of cancer without any treatments being given.",
  "content_length": 830,
  "content_tokens": 174,
  "embedding": []
 },
 {
  "title": "Immune System and Cancer Treatment",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The immune system is the body’s major defense mechanism against foreign invaders. A patient received an early kidney transplant; the kidney inadvertently contained renal cancer. Under the influence of immunosuppressant medications, the cancer spread widely through his body. In an attempt to control this, the immunosuppressant medications were stopped. Of course, the kidney rejected and had to be removed, but the patient’s cancer then went away as well because it too was allogeneic; it too came from the genome of the original donor. This was a huge inspiration that the immune system could be utilized to treat cancer.",
  "content_length": 623,
  "content_tokens": 126,
  "embedding": []
 },
 {
  "title": "Cancer Cells vs. Non-Cancer Cells",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A normal cell becomes a cancer cell due to the accumulation of mutations in DNA as these cells divide. Mistakes occur randomly during cell division. Cancer can be described but it doesn’t mean we understand it all. Hematological cancers are blood cancers; they begin from progenitors (stem cells) in the hematopoietic system. About 10% of all cancer deaths are due to hematological cancers. Epithelial cancers begin in the solid organs of the body. About 90% of all cancer deaths are due to epithelial cancers.",
  "content_length": 510,
  "content_tokens": 114,
  "embedding": []
 },
 {
  "title": "Chemotherapy and Immunotherapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The challenge is selectivity; how does one kill cancer and at the same time not kill normal cells? Selective killing of cancer without killing normal cells does not occur for virtually any cancer treatment: chemotherapy, radiation therapy, or even surgery. This is the promise of immunotherapy, its immense selectivity and sensitivity of recognition; it can recognize a single amino acid change in a protein and develop an immune response against it.",
  "content_length": 450,
  "content_tokens": 84,
  "embedding": []
 },
 {
  "title": "Immune System and Viral Infections",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Consider a viral infection, whether it’s the common cold or Coronavirus. The virus infects respiratory epithelium and replicates in these cells. Infected cells express viral proteins. The immune system has evolved to detect proteins or other molecules that are not part of the normal cells of the body. B lymphocytes (B cells) make antibodies. T lymphocytes (T cells) act by directly interacting with other tissues. Every 14 or 15 seconds, the heart is pumping out lymphocytes, they are circulating through the vascular system, sometimes extravasating into tissues, coming back into the lymphoid system and returning to the heart via the thoracic duct.",
  "content_length": 652,
  "content_tokens": 137,
  "embedding": []
 },
 {
  "title": "Lymphocytes and Immune Reaction",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "When the lymphocyte encounters a foreign antigen to which it can have reactivity, they stop at that location, extravasate into the tissue then they begin to divide. As lymphocytes divide they further recognize viral protein and start making molecules that can destroy the viral cell. They also call other cells into the area, macrophages and neutrophils, etc. This is an immune reaction. The antigen is eliminated by these cells. Now the cells leave; they’re not stimulated; they go back into circulation. There are now long lived lymphocytes patrolling the body for the rest of one’s life that can recognize these viral antigens. This is why vaccination works.",
  "content_length": 661,
  "content_tokens": 139,
  "embedding": []
 },
 {
  "title": "Cancer Cells and Immune System",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Cancer cells have unregulated growth because they don’t respond to cell cycle signaling. This is a result of somatic mutations; these are acquired mutations; people aren’t born with them. Mutations (changes in DNA) occur randomly as the cell divides; this can produce proteins that the immune system can recognize. The immune system in about 80% of patients with epithelial cancer recognizes mutations in this cancer. The problem is the immune reaction against the cancer is not rigorous enough. Effector T cells can be very aggressive in recognizing antigens. Regulatory T cells act to suppress immune reactions. For a tumor cell to grow and survive it develops certain properties such as suppressing the local immune reaction.",
  "content_length": 728,
  "content_tokens": 142,
  "embedding": []
 },
 {
  "title": "Interleukin-2 and Cancer Regression",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Interleukin 2 (IL-2) is a cytokine allows the growth of lymphocytes (T cells) in culture. IL-2 is also something that could be given to patients in vivo to stimulate the immune system. High doses of IL-2 caused toxicity. In 1984 a patient with widespread melanoma received IL-2 and was the first to show tumor regression after over 70 other patients had been treated. This patient is now alive, over 35 years later, free of disease.",
  "content_length": 432,
  "content_tokens": 100,
  "embedding": []
 },
 {
  "title": "Immunogenic Nature of Certain Cancers",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The success of treating melanoma with IL-2 had to do with the vast number of mutations in this type of cancer, about 400 mutations per tumor. The immune system recognizes the products of mutations. Melanoma is induced by a carcinogen, UV light. 80% of common cancers have between 60 to 70 and 150 mutations; the median would probably be around 110 but this would vary from cancer type to cancer type.",
  "content_length": 400,
  "content_tokens": 85,
  "embedding": []
 },
 {
  "title": "CAR T Cell Therapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The story of diffuse B-cell lymphomas that ultimately led to the biotech company KITE is fascinating. This is the story of how CAR T cell therapy was developed. T cells have receptors (TCR) that recognize antigens on the surface of a cancer cell. The T cell receptor is composed of alpha and beta chains. It binds the tiny peptides put on the surface of cancer cells on MHC class I molecules. 10-12 years ago Gideon Gross at the Weitzman Institute created an alternate way for a lymphocyte to recognize an antigen using antibodies.",
  "content_length": 531,
  "content_tokens": 115,
  "embedding": []
 },
 {
  "title": "Antibody Structure and Function",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The general structure of an antibody is made of 4 polypeptide chains and is shaped like a Y. The antigen-binding site is at the top of the Y and is a cleft between a variable light and variable heavy chain, VL and VH, respectively.",
  "content_length": 231,
  "content_tokens": 56,
  "embedding": []
 },
 {
  "title": "Chimeric T cells (CAR-T cells)",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Chimeric T cells (CAR-T cells) were created in which antibody recognition domains were added. The chimeric antigen receptor is part normal receptor (TCR, T cell receptor) ant part antibody; it utilizes the antigen-binding domains of the antibody. This allows the T cell (lymphocyte) to respond to what the antibody binds. The specificity of the CAR-T cell is determined by the antigen-binding domains of the antibody incorporated into the receptor (VH and VL).",
  "content_length": 460,
  "content_tokens": 101,
  "embedding": []
 },
 {
  "title": "CAR-T cells and Cancer",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "There are very few molecules on the cell surface unique to a cancer and CAR-T cells can be designed to recognize them. The immune system will destroy a normal cell or a cancer cell; targeting antigens unique to cancer cells is essential. One target antigen for lymphomas and leukemias is CD19. Generation of CAR T cells that recognize CD19 eliminated lymphomas, leukemias, and all normal B cells. One can live without B cells because antibodies can be provided with infusions. This work resulted in the first cell and gene therapy ever approved by the FDA.",
  "content_length": 556,
  "content_tokens": 119,
  "embedding": []
 },
 {
  "title": "CAR-T cells and Solid Cancers",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Currently CAR T cells cannot be used to treat solid cancers (Non-hematologic cancers). A molecule on the cell surface unique to the cancer is needed for CAR T cell therapy. CAR T cells are exquisitely sensitive; patients died when molecules from normal cells were targeted. A monoclonal antibody unique to molecules on the surface of cancer cells, not found on normal cells is needed to develop CAR T cell therapy (to make a chimeric T cell receptor).",
  "content_length": 451,
  "content_tokens": 94,
  "embedding": []
 },
 {
  "title": "Tumor Infiltrating Lymphocytes (TILs)",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "T cells that infiltrate the tumor are called TILs. Looked in melanoma patients for T cells that could recognize the tumor and grew these cells to large numbers in vitro by culturing them with IL-2. Treating patients with these TILs grown in vitro in IL-2 yielded a response rate of 30-35%. TILs were isolated from melanoma patients, grown in vitro in the presence of IL-2 and given back to melanoma patients.",
  "content_length": 408,
  "content_tokens": 96,
  "embedding": []
 },
 {
  "title": "Gene Therapy and T cells",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The safety and feasibility of using gene therapy to add genes to T cells was demonstrated by adding the bacterial gene for neomycin resistance. This allowed these modified T cells to be tracked in patients. The safety of genetically engineered T cells was accessed and paved the way for modifying T cells in ways to improve their ability to kill cancer cells.",
  "content_length": 359,
  "content_tokens": 67,
  "embedding": []
 },
 {
  "title": "Checkpoint Inhibitors in Cancer Therapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Checkpoint inhibitors suppress T cell activity. Checkpoint inhibitors include targeting CTLA-4 and PD-1; these are called anti-CTLA-4 and anti-PD-1. CTLA-4 and PD-1 put the brakes on inflammatory T cell activity. There are inhibitors in every physiologic system and one way this can occur is with molecules on the cell surface that can engage with receptors. CTLA-4 and PD-1 are often expressed by cancer cells and function to put the brakes on T cell activity. Releasing these brakes with anti-CTLA-4 and anti-PD-1 antibodies allows the T cells to be very active and attack certain cancers.",
  "content_length": 591,
  "content_tokens": 138,
  "embedding": []
 },
 {
  "title": "Cancer and Checkpoint Inhibitor Treatment",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Cancers that have large numbers of mutations, often due to mutations in mismatch repair genes are: melanoma, kidney cancer, Lynch syndrome, and microsatellite unstable tumors (MSI). These cancers respond well to checkpoint inhibitor treatment. Common epithelial cancers respond poorly to checkpoint inhibitor treatment. These cancers result in 90% of deaths in patients. The majority of cancer patients do not respond do simply taking off the brakes CTLA-4 and PD-1 exert on T cells. Hopefully combinations of treatments using checkpoint modulators will be more effective in the future. Success of checkpoint inhibitors in some cancer patients was still a major step forward. It is easy to apply because it only requires injection of an antibody.",
  "content_length": 746,
  "content_tokens": 141,
  "embedding": []
 },
 {
  "title": "Adoptive Cell Therapy",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Treatment of cancer with CAR-T cells targeting CD19 on B cells (to eradicate lymphoma), checkpoint modulators that target CTLA-4 and PD-1 have durable effects on cancers with a high number of mutations, in some cases IL-2 is effective; these are the low hanging fruit of immunotherapy which took 50 years of work to develop. These low hanging fruit are pillars of immunotherapy that will provide a path forward. The promise of adoptive cell therapy. Consider the half a million patients with solid organ metastatic cancer—80% have antigens unique to them but not occurring in high enough frequency to respond to a checkpoint inhibitor alone. Can patients be cured with adoptive cell therapy in a customized format? Adoptive cell therapies are outlined in the figure below. They can utilize T cells isolated from the patients (TIL’s) and grown in culture. Or they could utilize gene modified T cells engineered to recognize specific cancer antigens. Adoptive cell therapy can work for multiple tumor types such as liver tumors, bile duct cancers breast cancer, colon cancer, and cervical cancer.",
  "content_length": 1094,
  "content_tokens": 226,
  "embedding": []
 },
 {
  "title": "Cancer Antigens and T-Cell Reactivity",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Now that we know the exact T-cell receptor sequences (it’s been cloned and isolated) targeting cancer antigens is almost an engineering problem. Libraries of receptors have been isolated that bind p53 and KRAS. These receptors can be used to turn a normal lymphocyte (T cell) into one that can attack cancer. The focus of his work is now how to utilize T cell reactivity to the unique mutations in solid epithelial cancers and get them to respond to immunotherapy. These are the cancers that cause 90% of all cancer deaths. Optimism for using immunotherapy to cure all cancers. The recognition that virtually every solid tumor has novel peptides that can be recognized by a patient’s own immune system. It’s a recent advancement to realize that these unique mutations in cancer cells are the antigens; T cells can recognize them thereby allowing the immune system to attack cancer cells.",
  "content_length": 887,
  "content_tokens": 187,
  "embedding": []
 },
 {
  "title": "Challenges in Oncology",
  "date": "September 27, 2021",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "In oncology, 80-90% of people that walk in the door die; it’s hard to imagine. Patients that come to the NIH have gone through every standard therapy. Patients coming here our out of options. These patients have the most advanced, aggressive cancers imaginable. The patients probably wouldn’t be expected to live more than 6 months. Saving 20% of them is remarkable, but 80% still die. Some treatments don’t work but actually cause some harm. This is what happens when new therapies are being developed. They have limited tools but that’s all one has, day in and day out; it’s very trying. Working toward better treatments gives hope to the difficult job oncologists face.",
  "content_length": 672,
  "content_tokens": 153,
  "embedding": []
 }
]